Unicycive Therapeutics (UNCY) director granted 47,941 RSUs with staged vesting

Q: What equity award did Unicycive Therapeutics (UNCY) director Sara Kenkare-Mitra receive?

Sara Kenkare-Mitra received 47,941 Restricted Stock Units from Unicycive Therapeutics as an equity award. The RSUs are payable in common stock and represent a form of stock-based compensation tied to her ongoing role as a director.

Q: How do the 47,941 RSUs granted at UNCY vest over time?

Of the 47,941 RSUs , 19,976 shares vest upon grant and 3,995 shares vest monthly over seven months starting June 1, 2026. This creates a short vesting schedule combining immediate and monthly vesting tranches.

Q: What conditions apply to Sara Kenkare-Mitra’s UNCY RSU vesting?

The vesting of the 47,941 RSUs is subject to Kenkare-Mitra’s continued service with Unicycive Therapeutics. Both the immediate vesting tranche and the monthly vesting installments require her to remain in service for the specified periods.

Q: What is the total equity position reported after this UNCY Form 4/A transaction?

Following this award, Kenkare-Mitra is reported to hold 47,941 Restricted Stock Units directly. Each RSU is payable solely in Unicycive Therapeutics common stock, aligning her compensation with the company’s equity performance.

Q: Is there a cash purchase price for the 47,941 RSUs reported at UNCY?

The filing lists a per-unit price of $0.0000 for the 47,941 RSUs , indicating these units were granted as compensation rather than purchased for cash in the open market.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics, Inc. director Sara Kenkare-Mitra reported an equity compensation award of 47,941 Restricted Stock Units on May 14, 2026. The RSUs are payable solely in common stock; 19,976 shares vest immediately and 3,995 vest monthly over seven months from June 1, 2026, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kenkare-Mitra Sara

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units ^F1	47,941	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 47,941 shares (Direct)

Footnotes (1)

F1. Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Key Figures

RSUs granted: 47,941 units Immediate vesting tranche: 19,976 shares Monthly vesting amount: 3,995 shares +3 more

6 metrics

RSUs granted 47,941 units Restricted Stock Units awarded to director Sara Kenkare-Mitra on May 14, 2026

Immediate vesting tranche 19,976 shares Portion of RSUs vesting upon grant

Monthly vesting amount 3,995 shares Shares vesting each month over seven months beginning June 1, 2026

Vesting period length 7 months Monthly vesting duration starting June 1, 2026

Total RSUs after transaction 47,941 units Direct holdings following the reported award

Grant price per RSU $0.0000 per unit Listed transaction price for the RSU grant

Key Terms

Restricted Stock Units, vesting, continued service

3 terms

Restricted Stock Units financial

"Represents grant of restricted stock units payable solely in common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"19,976 shares vest upon grant and 3,995 vest monthly over 7 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued service financial

"vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 04:16 PM Accepted by SEC EDGAR 07/28/2026 - 04:15 PM

FAQ

What equity award did Unicycive Therapeutics (UNCY) director Sara Kenkare-Mitra receive?

Sara Kenkare-Mitra received 47,941 Restricted Stock Units from Unicycive Therapeutics as an equity award. The RSUs are payable in common stock and represent a form of stock-based compensation tied to her ongoing role as a director.

How do the 47,941 RSUs granted at UNCY vest over time?

Of the 47,941 RSUs, 19,976 shares vest upon grant and 3,995 shares vest monthly over seven months starting June 1, 2026. This creates a short vesting schedule combining immediate and monthly vesting tranches.

What conditions apply to Sara Kenkare-Mitra’s UNCY RSU vesting?

The vesting of the 47,941 RSUs is subject to Kenkare-Mitra’s continued service with Unicycive Therapeutics. Both the immediate vesting tranche and the monthly vesting installments require her to remain in service for the specified periods.

What is the total equity position reported after this UNCY Form 4/A transaction?

Following this award, Kenkare-Mitra is reported to hold 47,941 Restricted Stock Units directly. Each RSU is payable solely in Unicycive Therapeutics common stock, aligning her compensation with the company’s equity performance.

Is there a cash purchase price for the 47,941 RSUs reported at UNCY?

The filing lists a per-unit price of $0.0000 for the 47,941 RSUs, indicating these units were granted as compensation rather than purchased for cash in the open market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kenkare-Mitra Sara

(Last)

(First)

(Middle)

C/O UNICYCIVE THERAPEUTICS, INC.

1975 W. EL CAMINO REAL, SUITE 204

(Street)

MOUNTAIN VIEW

CALIFORNIA

94040

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/21/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	05/14/2026		A		47,941		⁽¹⁾	⁽¹⁾	Common Stock	47,941	$0	47,941	D

Explanation of Responses:

1. Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

	/s/ Sara Kenkare-Mitra	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR